Log in | Join Free | china | japan | germany

palivizumab

Request For Quotation
palivizumab Suppliers list
Company Name: LGM Pharma  
Tel: 1-(800)-881-8210
Email: inquiries@lgmpharma.com
Products Intro: Product Name:PalivizuMab
CAS:188039-54-5
Purity:Typically NLT 98%
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725
Email: waley188@sohu.com
Products Intro: Product Name:palivizuMab
CAS:188039-54-5
Purity:99% Package:25kg
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Products Intro: Product Name:Palivizumab
CAS:188039-54-5
Purity:95% Package:2mg;5mg;10mg
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 17754423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Palivizumab
CAS:188039-54-5
Purity:95% Package:100ug;500ug;1mg
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Palivizumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
palivizumab Basic information
Product Name:palivizumab
Synonyms:palivizumab;Research Grade Palivizumab(DVV02801);Synagis
CAS:188039-54-5
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
palivizumab Structure
palivizumab Chemical Properties
storage temp. Store at -20°C
Safety Information
Hazardous Substances Data188039-54-5(Hazardous Substances Data)
MSDS Information
palivizumab Usage And Synthesis
IndicationsPalivizumab (Synagis) is a humanized monoclonal antibody directed against the highly conserved A antigenic site of the F protein on the surface of RSV. It contains 95% human and 5% murine antibody sequences and tends to have little immunogenicity in humans. Palivizumab is composed of the human framework region of the IgG-1κ-chain joined to the antigen-binding regions of a mouse monoclonal antibody. Palivizumab neutralizes RSV and inhibits its ability to fuse with host cell membranes. Resistant strains of RSV have been derived in vitro but have not been found in clinical isolates to date.
Clinical UsePalivizumab is used to prevent serious lower respiratory tract infection due to RSV. It is used only in high-risk children who are younger than 24 months of age and have bronchopulmonary dysplasia or chronic lung disease that required treatment in the previous 6 months. It is also indicated for premature infants (less than 32 weeks’ gestation) until the age of 6 to 12 months. Palivizumab can reduce the incidence of RSV-related hospitalization by approximately half.The safety and efficacy of palivizumab in the treatment of RSV disease have not been established.
Side effectsSerious adverse reactions caused by palivizumab are rare.Mild erythema and pain may occur at the injection site.Although no anaphylactoid reactions have been reported to date, the possibility of this reaction exists because palivizumab is a protein.
palivizumab Preparation Products And Raw materials
Tag:palivizumab(188039-54-5) Related Product Information
Follicle stimulating hormone Secukinumab Daratumumab OMALIZUMAB Dulaglutide Trastuzumab emtansine Ranibizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Eculizumab Panitumumab Trastuzumab Matuzumab ticilimumab tremelimumab CNTO 148 Aflibercept abciximab nimotuzumab belimumab